Greenberg Harry B, Estes Mary K
Department of Medicine and Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305-5119, USA.
Gastroenterology. 2009 May;136(6):1939-51. doi: 10.1053/j.gastro.2009.02.076. Epub 2009 May 7.
Rotaviruses cause life-threatening gastroenteritis in children worldwide; the enormous disease burden has focused efforts to develop vaccines and led to the discovery of novel mechanisms of gastrointestinal virus pathogenesis and host responses to infection. Two live-attenuated vaccines for gastroenteritis (Rotateq [Merck] and Rotarix) have been licensed in many countries. This review summarizes the latest data on these vaccines, their effectiveness, and challenges to global vaccination. Recent insights into rotavirus pathogenesis also are discussed, including information on extraintestinal infection, viral antagonists of the interferon response, and the first described viral enterotoxin. Rotavirus-induced diarrhea now is considered to be a disease that can be prevented through vaccination, although there are many challenges to achieving global effectiveness. Molecular biology studies of rotavirus replication and pathogenesis have identified unique viral targets that might be useful in developing therapies for immunocompromised children with chronic infections.
轮状病毒在全球范围内导致儿童出现危及生命的肠胃炎;巨大的疾病负担促使人们致力于研发疫苗,并推动了对胃肠道病毒发病机制和宿主感染反应新机制的发现。两种用于肠胃炎的减毒活疫苗(Rotarix[默克公司生产]和Rotateq)已在许多国家获得许可。本综述总结了关于这些疫苗的最新数据、它们的有效性以及全球疫苗接种面临的挑战。还讨论了轮状病毒发病机制的最新见解,包括肠外感染、干扰素反应的病毒拮抗剂以及首次描述的病毒肠毒素等信息。尽管实现全球有效性面临诸多挑战,但轮状病毒引起的腹泻现在被认为是一种可通过接种疫苗预防的疾病。对轮状病毒复制和发病机制的分子生物学研究已经确定了独特的病毒靶点,这些靶点可能有助于为患有慢性感染的免疫功能低下儿童开发治疗方法。